ArticleJournal of medical systems2026
DualKG-DC: A Drug-Centric Dual-Layer Knowledge Graph Framework for Drug Combination Prediction.
Article in Journal of medical systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Most existing approaches to drug combination discovery are disease-centered, aiming to identify drug pairs for specific diseases. Complementarily, a drug-centered strategy starts from known drug combinations and explores new therapeutic indications, facilitating translational applications by leveraging combinations with established safety profiles. Here, we introduce DualKG-DC, a drug centered computational framework that provides a complementary perspective by identifying potential disease indications for a given drug combination. The dual layer knowledge graph architecture, which is pretrained on a foundation biomedical knowledge graph and subsequently refined on a task specific drug combination subgraph, may reduce reliance on large, labeled datasets by leveraging existing knowledge on drug targets, biological pathways, and observed phenotypic effects. In systematic benchmarking against three state-of-the-art models, DualKG-DC outperformed all comparison models, achieving an average Hits@10 of 0.48, MRR of 0.30, AUROC of 0.99, and AUPRC of 0.31. Notably, in cold start scenarios, DualKG-DC outperformed baseline methods in predicting indications for unseen drug combinations, achieving superior results with an average Hits@10 score of 0.32, an MRR of 0.18, an AUROC of 0.98, and an AUPRC of 0.23. These results highlight DualKG-DC as an effective platform for systematically discovering therapeutic opportunities of drug combinations. By leveraging a dual-layer architecture, the model enables effective knowledge transfer, enhancing predictive performance and robustness, particularly for previously unseen drug combinations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.